Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
2.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
3.
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
4.
Commercial Insight: CNS Market Overview - Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors
5.
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market
6.
Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
7.
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline set to offer only modest improvements
8.
Stakeholder Opinions: Heart Failure - When drugs do not work
9.
Pipeline Insight: Breast Cancer - Recent approvals increase pressure on pipeline candidates
10.
Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential
Best Sellers:
1.
Primary Brain Cancer
2.
Drug Delivery Global Industry Guide
3.
The Convergence of Biomarkers and Diagnostics: Therapy area analyses, key products and future trends
4.
The Fastest Growing Biotechnology Companies: Growth strategies, comparative analyses and company profiles
5.
BioNewsCast Press Release Distribution Service
6.
Pharmaceutical Growth Opportunities in Brazil, Russia, India and China - Healthcare reform, market dynamics and key players
7.
Cell Therapy - Technologies, Markets and Companies
8.
Cytogenetics - technologies, markets and companies
9.
Molecular Diagnostics Markets
10.
The Future of Targeted Therapeutics Key technologies, new therapy area applications and leading players
The Global Antibacterials Market R&D Pipelines Market Analysis and Competitive Landscape
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.
Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance. In addition, a number of new drug classes such as dihydrofolate reductase inhibitors (DHFR) are under evaluation which are effective in multi drug resistant organisms.
This report examines each of the antibacterial classes in turn, assessing the market potential and application in hospital and community-acquired infections.
The following product classes are analyzed in this report:
* aminoglycosides
* carbapenems
* cephalosporins
* dihydrofolate reductase inhibitors
* glycopeptides
* ketolides
* lipopeptides
* macrolides
* penicillins
* oxazolidinones
* pleuromutulins
* quinolones
The report assesses the overall antibacterial market, key classes and the drivers and resistors influencing their prescription. The report provides an overview of key products in each category, summarizing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation and by leading players and their products and analyzes market trends.
The report also examines promising pipeline products and their potential impact on the prescription of current and new antibacterial agents and the future of the antibacterial market.
Key Features of this report:
* Overview of the antibacterial market, including the main infectious agents, therapeutic drug classes and key players.
* In-depth analysis of different classes of antibacterial agents, including leading antibacterial agents and a summary of leading brands within each class.
* Comprehensive facts and figures for the antibacterial market, including main players and drug class break-downs.
* Future trends in the antibacterial marketplace, driven by drug resistance and patient demographics.
* Outlook for the antibacterial market, including the emergence of novel therapies and the impact of generics.
Published: August 28, 2007
Pages: 126
PDF Format
Table of Contents
Price
Single User PDF $2499.00
Corporate Wide Licence PDF $5499.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.